For example, Felicitas et al. [31] observed DNMT3 A mutations in only 2.6% of 193 myelodysplastic syndrome patients, while Hideki et al. [32] reported ASXL1 as the most frequent mutation (30.8%) in a cohort of SETBP1-mutated myeloid malignancies, with DNMT3 A mutations found in only 11.5%. This evidence concerns the gene ASXL1 and myelodysplastic syndrome.